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Abstract
Background The Dutch Pancreatic Cancer Group initiated
the national, multicentre, controlled PREOPANC trial, ran-
domising between preoperative radiochemotherapy and di-
rect explorative laparotomy for patients with (borderline)
resectable pancreatic cancer. The aim of this dummy run
is to evaluate compliance with the radiotherapy protocol of
this trial, and the quality of delineation and radiation plans.
Methods Eleven radiation oncology departments open for
accrual of patients in the PREOPANC trial were provided
with all necessary information of a selected ‘dummy’ pa-
tient. Each institute was asked to delineate the target vol-
umes, including gross tumour volume, internal gross tu-
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mour volume (iGTV), internal clinical target volume, and
planning target volume. The institutions were also asked to
provide a radiation treatment plan in accordance with the
PREOPANC trial protocol.
Results The range of the iGTV was 19.3–77.2 cm3 with
a mean iGTV of 41.5 cm3 (standard deviation 14.8 cm3).
Nine institutions made a treatment plan using an arc tech-
nique for treatment delivery, one an intensity modulated
technique and one a 3-field conformal technique. All in-
stitutions reached the prescribed target coverage, without
exceeding the organs at risk constraints. The institution
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a more sophisticated technique (e. g. volumetric modulated
arc therapy) to reduce the dose to the spinal cord.
Conclusion All institutions showed acceptable deviations
from the PREOPANC trial protocol and achieved an ac-
ceptable quality of delineation and radiation technique. All
institutions were allowed to continue participation in the
PREOPANC trial.
Keywords Planning techniques · Computed tomography ·
Clinical protocols · Fiducial markers · Clinical trial
Qualitätssicherung in der PREOPANC-Studie




Hintergrund Die niederländische Gruppe für Bauchspei-
cheldrüsenkrebs (Dutch Pancreatic Cancer Group, DPCG)
initiierte die nationale und multizentral kontrollierte PREO-
PANC-Studie, worin die präoperative Radiochemotherapie
mit der direkten explorativen Laparotomie für Patienten
mit (grenzwertig) resektablen Pankreaskarzinomen vergli-
chen wird. Ziel des „dummy runs“ ist es, die Übereinstim-
mung mit dem Strahlentherapieprotokoll dieser Studie und
die Qualität der Zielvolumenkonturierung und der Bestrah-
lungspläne zu evaluieren.
Methoden Insgesamt 11 Abteilungengen für Radioonkolo-
gie, die offen für Patienten der PREOPANC-Studie waren,
erhielten alle notwendigen Informationen für einen ausge-
wählten „Dummy“-Patienten. Jedes Institut wurde gebeten,
die Zielvolumina einzuzeichnen, einschließlich des makro-
skopischen Tumorvolumens, des internen makroskopischen
Tumorvolumens (iGTV), des internen klinischen Zielvolu-
mens und des Planungszielvolumens. Außerdem erstellte
jedes Institut einen Bestrahlungsplan in Übereinstimmung
mit dem PREOPANC-Protokoll.
Ergebnisse Der Bereich des iGTV betrug 19,3–77,2 cm3
mit einem durchschnittlichen iGTV von 41,5 cm3 (Stan-
dardabweichung 14,8 cm3). Es wurden 9 VMAT-Pläne, ein
IMRT-Plan und ein Plan mittels konformaler 3-Felder-
Technik erstellt. Alle Institutionen erreichten die vor-
geschriebene Zielabdeckung ohne Einschränkung oder
Überschreitung der erlaubten Dosis in den Risikoorga-
nen. Der Institution, die die 3-Felder-Technik verwendete,
wurde empfohlen, eine anspruchsvollere Technik (z. B.
volumenmodulierte Arc-Therapie) zu verwenden, um die
Rückenmarkdosis zu reduzieren.
Schlussfolgerung Alle Institutionen zeigten akzeptable
Abweichungen vom PREOPANC-Studienprotokoll und
erreichten eine akzeptable Qualität der Zielvolumenkontu-
rierung und der Bestrahlungstechnik. Allen Institutionen
wurde die weitere Teilnahme an der PREOPANC-Studie
erlaubt.
Schlüsselwörter Planungstechnik ·
Computertomographie · Klinisches Protokolle · Fiducial-
Marker · Klinische Studie
Background
Pancreatic cancer is the fourth largest cancer-related cause
of death worldwide, with an overall 5-year survival rate of
2–7% [1–4]. Although approximately 15% of patients are
diagnosed with a seemingly resectable tumour, 10–35% of
these tumours prove to be irresectable during explorative
laparotomy [5]. Also, although some studies suggest that
the percentage of resectable tumours may be increased by
preoperative radiochemotherapy, those studies were mainly
single-arm phase II trials and many did not report using the
intention-to-treat approach [5].
The Dutch Pancreatic Cancer Group (DPCG) started
the multicentre, randomised, controlled PREOPANC trial
(Netherlands Trial Registry: NTR 3709), which became
open for accrual in April 2013 [6]. In this phase III trial,
patients with (borderline) resectable pancreatic tumours
are randomized between (1) direct explorative laparotomy
and (2) preoperative radiochemotherapy followed by ex-
plorative laparotomy.
For pancreatic cancer, it is well known that target vol-
ume delineation can be difficult [7]. In our department,
the planning CT scan is combined with a contrast medium
and a four-dimensional CT scan (4DCT) to determine the
respiratory-induced motion of the tumour and neighbour-
ing organs [8]. Because of the large day-to-day variation
in tumour position, in our clinic we currently use intra-
tumoural fiducial markers for delineation and daily online
position verification [8–12]. The radiation oncologist delin-
eates the gross tumour volume (GTV) on the CT scan and
expands this volume to encompass the GTV in all respira-
tory phases. This expanded volume is defined as the internal
gross tumour volume (iGTV). The iGTV combined with an
additional margin forms the internal clinical target volume
(iCTV), which is then expanded to create the planning tar-
get volume (PTV).
A dummy run procedure at the beginning of a clinical
trial is a good tool to improve protocol compliance with the
radiotherapy prescriptions and to improve uniformity of the
treatment. In multicentre trails, a dummy run can diminish
heterogeneity in treatment quality and can also be used to
detect correctable variations in treatment [13–18].
The aim of this dummy run procedure was to evaluate
compliance with the radiotherapy protocol, and the unifor-
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mity of delineation and treatment planning, among institu-
tions participating in the DPCG PREOPANC trial.
Methods
General
All 11 radiation oncology departments participating in the
PREOPANC trial were asked to participate in the dummy
run and were encouraged to complete the dummy run be-
fore the start of patient accrual. The opening for accrual
varied between the different institutions: the first opened in
April 2013 and the last in November 2015. In the PRE-
OPANC trial, the preoperative radiochemotherapy consists
of a total dose of 36 Gy in 15 fractions of 2.4 Gy (5 frac-
tions/week), with concurrent gemcitabine (1000 mg/m2 on
days 1, 8 and 15) preceded and followed by a cycle of gem-
citabine (1000 mg/m2 on days 1 and 8) with one week rest
in between the three cycles [6].
Dummy run procedure
The ‘dummy’ patient had a borderline resectable pancre-
atic tumour in the pancreatic tail and was selected by the
Quality Assurance (QA) team. This team consisted of one
radiation oncologist (GT), one radiation oncology resident
(EV), two medical physicists (AB, JV) and two researchers
(EL, AH). Institutions were provided with a set of images
and clinical data of this ‘dummy’ patient to be uploaded
to the local delineation and treatment planning system. The
data contained the diagnostic CT scan (4 phases with vas-
cular contrast) with the radiological report, the planning CT
scans, including a contrast-enhanced 3DCT (fast scan) and
a 4DCT, the dummy run instructions and a questionnaire.
Prior to the planning CT scan, the patient had three
intratumoural fiducial markers (Visicoil, Core Oncology,
Santa Barbara, CA, USA) implanted by the gastroenterolo-
gist during endoscopic ultrasound. In our institution, intra-
tumoural fiducial markers are standard practice for daily
position verification of the tumour with cone beam CT
[11, 12]. The planning CT scan images were acquired us-
ing a GE LightSpeed RT16 scanner (General Electric Co.,
Waukesha, WI, USA): slice thickness 2.5 mm. First, the
CT scan with vascular contrast was obtained (fast scan),
followed by a 4DCT scan which provided the respiratory-
induced motion of the tumour in 10 respiratory phase scans.
In addition, a maximum intensity projection and an aver-
age intensity projection (Ave-IP) were reconstructed from
the data of the 10 respiratory phase scans. On the provided
planning CT scan, the organs at risk (OARs; kidneys, liver
and spinal cord) were already delineated to exclude dosi-
metric differences due to differences in OAR delineation.
The responsible radiation oncologists were instructed to
delineate and expand the target volumes (GTV, iGTV, iCTV
and PTV) and supply a radiation plan according to the
PREOPANC trial protocol (Electronic Supplementary Ma-
terial; [6]). The radiation oncologists received this protocol
at the moment the institution had received approval for in-
clusion of patients in the PREOPANC trial. Furthermore,
the responsible radiation oncologists were asked to fill out
a questionnaire concerning treatment facilities and proce-
dures. The QA team performed the quality evaluation of all
submissions.
Delineation prescriptions
Observers were asked to delineate the GTV on the Ave-
IP projection according to the protocol (Electronic Supple-
mentary Material). This GTV had to be expanded to en-
compass the tumour on all respiratory phases of the 4DCT
scan, thus creating the iGTV. The iCTV was defined as the
iGTV with a 5-mm uniform margin to account for possible
microscopic tumour extensions. An alternative (but more
time-consuming) possibility was to delineate the GTV in
all respiratory phases, expanding each of these GTVs with
5 mm and summing these volumes, forming the internal tar-
get volume (ITV). The PTV included the iCTV (or ITV)
plus a 10-mm uniform margin. Consultation of a diagnostic
radiologist during the delineation process was allowed.
Treatment planning technique
In the PREOPANC trial, at least a 3D conformal treatment
delivery technique was required (Electronic Supplementary
Material; [6]). More sophisticated techniques, such as in-
tensity-modulated radiation therapy (IMRT) and volumet-
ric modulated arc therapy (VMAT) were also allowed. The
dose of 3600 cGy in 15 fractions should be specified ac-
cording to the International Commission on Radiation Units
and Measurements (ICRU) guidelines; at least 95% of the
prescribed dose should cover ≥98% of the PTV [19–21].
For the OARs, the prescriptions in the PREOPANC trial
were recommended in equivalent doses (fraction dose of
2 Gy). Due to a fraction dose of 2.4 Gy, we also supplied
the physical doses of the constraints for the OARs to cal-
culate treatment planning. If the mean physical dose to one
kidney exceeded 1680 cGy, irradiation of the contralateral
kidney should be avoided as much as possible. The mean
physical dose of the liver was not to exceed 2640 cGy.
Since the total dose in the slightly hypofractionated sched-
ule of 36 Gy is relatively low, the dose to the spinal cord
will (at maximum) be well below the tolerance. Similarly,





For assessment of the first three institutions, we arranged
a meeting with all members of the QA team to ensure that
the procedure of evaluating the target delineation and treat-
ment planning/dosimetry was uniform, and conform the
dummy run protocol. The first five delineations were eval-
uated by the senior radiation oncologist (GT) and the ra-
diation oncology resident (EV) together (both experienced
in delineation of pancreatic tumours) This evaluation deter-
mined whether the delineation was adequate with respect
to the iGTV location and delineation, compared with the
tumour seen on the diagnostic CT and described in the di-
agnostic report. After a standard procedure of evaluating
the delineations was drafted between the radiation oncolo-
gist and the resident, the radiation oncology resident alone
assessed the remaining six delineations. The mean volumes
of the iGTV and PTV, as well as the ratio of the smallest
and largest iGTV and PTV, were calculated.
The treatment plans were evaluated based on dose cover-
age of the PTV, dose to the OARs, and the radiation delivery
technique used. The conformity index (CI) described by the
Radiation Oncology Therapy Group (RTOG), defined as the
ratio between the volume enclosed by the reference isodose
(95%) and the PTV [22], was used as a measure for confor-
mity with the high-dose region to the PTV. The first three
submitted treatment plans were evaluated by the entire QA
team to assess the standard procedure that was drafted for
this dummy run in the protocol. After evaluating the proce-
dure, the remaining treatment plans and dosimetric param-
eters were evaluated by one of the researchers (EL) and the
radiation oncologist resident (EV).
An overall conclusion concerning protocol compliance
was made for each institution. Feedback was provided to
each participating institution on an individual basis within
6 weeks after submission. In case of deviations that occur
in the majority of the participating institutions, the protocol
instructions were to be modified.
Table 1 Questionnaire outcomes
Institution Indication radiotherapy Patients treated/year Image modalities for delineation Delineation time (min)
1 Palliative intent only Not stated Diagnostic CT, 4DCT, MRI 180
2 Irresectable tumours 2 Diagnostic CT, PETCT 45
3 Not applicable 0 Not applicable 45
4 Palliative setting only Not stated 4DCT scan 45
5 Not applicable 0 Diagnostic CT, 4DCT 90
6 Palliative/neoadjuvant 30 Diagnostic CT, 4DCT, MRI, PET/CT 120
7 Not stated 15 Diagnostic CT, 4DCT, ultrasound 60
8 Irresectable tumours 5 Diagnostic CT, 4DCT 60
9 Not applicable 0 Not applicable 90
10 Long course radiotherapy 5 4DCT, PETCT 60
11 Not stated 15 4DCT 120
Results
All 11 institutions submitted the delineation and treatment
plan for the ‘dummy’ patient and the questionnaire.
Questionnaire
Only three institutions indicated they treated >10 patients
per year (Table 1). The delineation of the target volumes
for the ‘dummy’ patient was experienced as moderately
difficult. Most institutions (8 of 11) used 4DCT scans for
delineation in patients with pancreatic cancer. In three in-
stitutions, fiducial markers were placed in the tumour as
part of the routine treatment; two of those use 3–4 Visicoil
intratumoural markers per patient; one of these institutions
used fiducial markers only for stereotactic treatment of the
pancreas. In this institution 3 fiducials are consecutively
placed in the tumour or close to the tumour (within 3 cm of
the tumour).
Target volume delineation
The range of the iGTV was 19.3–77.2 cm3 (Fig. 1),
with a mean iGTV of 41.5 cm3 (standard deviation [SD]
14.8 cm3). The ratio between the largest to the small-
est iGTV was 4.0. The range of the PTV volume was
162.4–341.6 cm3 (Fig. 2), with a mean PTV volume of
251.4 cm3 (SD 48.7 cm3; Fig. 3). In most cases, the iGTV
was found to be smaller than expected when compared with
the tumour seen on the diagnostic CT scan and described
in the diagnostic report (Fig. 1). In 8 of the 11 institutions,
in some CT slices, the ventral side of the tumour was
delineated with tight borders. All these tumour borders
were included in the iCTV, even though the iCTV is not
the correct target volume for macroscopic tumour volume.
One institution delineated the tumour larger than described
on the diagnostic CT (especially in the caudal direction)
and had the largest iGTV of all the institutions. For one
K
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Fig. 1 Gross tumour volumes (GTVs) of one institution (red) and in-
ternal gross tumour volumes (iGTVs) of 10 institutions projected on the
average scan of the four-dimensional computed tomography (4DCT).
One intratumoural fiducial marker is visible within the delineated tar-
get. Colours: institution 1: orange; 2: yellow; 3: light blue; 4: green;
5: pink; 6: dark green; 7: brown; 8: dark blue; 9: black; 10: red, 11:
purple
Fig. 2 Planning target volumes (PTVs) of the 11 institutions pro-
jected on the average scan of the four-dimensional computed tomogra-
phy (4DCT), with one intratumoural fiducial marker visible within the
PTVs. Colours: institution 1: orange; 2: yellow; 3: light blue; 4: green;
5: pink, 6: dark green; 7: brown; 8: dark blue; 9: black; 10: red; 11:
purple
institution (institution #10), the iGTV was created after
a margin of 5 mm was added to the GTV for the CTV.
In this case, the respiration motion of the tumour was ac-
counted for in the iCTV; therefore, no iGTV was available
and we included the GTV as delineated in Figs. 1 and 3.
All institutions used the correct margins to obtain iCTV
and PTV.
Treatment planning/dosimetry
The majority of institutions (82%) used VMAT for treat-
ment delivery. Institution #7 used IMRT and institution #2
used a 3-field conformal technique.




1 Large iGTV compared to other institutions
2 Some CT slices with tight borders iGTV in ventral direc-
tion
Conformal technique (3D conformal); advised to use
a more sophisticated technique to lower the dose to the
spinal cord
3 Tight borders iGTV in medial, lateral and ventral direc-
tion
4 Tight borders iGTV in all directions; smallest iGTV of all
the institutions. Not all fiducials incorporated in iGTV
5 Tight borders iGTV in ventral and medial direction
6 No recommendations for delineation
7 Tight borders iGTV in ventral direction (only central part
of the tumour)
Used IMRT technique (6 MV), advised to use 10 MV
energy
8 Tight borders iGTV in ventral directions
9 Tight borders iGTV in ventral and dorsal direction
10 Tight borders GTV in dorsal direction
GTV expansion for ten respiratory phases after adding
5 mm margin for CTV
11 Tight borders iGTV in ventral direction
iGTV internal gross tumour volume, CTV clinical target volume,
IMRT intensity-modulated radiation therapy, VMAT volumetric modu-
lated arc therapy
The dose prescription to the PTV (V95% ≥ 98%) was
achieved in all treatment plans. The mean CI was 1.16
(range 1.04–1.52), with the largest CI in the 3-field con-
formal plan (Fig. 3a). The doses to the OARs are shown
in Fig. 3c. The mean left kidney dose was 579 cGy (range
326–849 cGy) and the mean right kidney dose was 283
cGy (range 68–564 cGy). The mean liver dose was 519
cGy (range 394–690 cGy), and the mean maximum dose to
the spinal cord was 1724 cGy (range 1214–3016 cGy). The
highest dose to the spinal cord was observed in the 3-field
conformal treatment plan.
Verification of the protocol
Some minor recommendations concerning these delin-
eations were given as feedback to the institutions. In most
of the institutions (8 of 11), suggestions for the delineations
concerned the tight borders of the iGTV in ventral direc-
tion; it was advised to include these borders in the iGTV
(Table 2). We advised institution #7 to use a more sophis-
ticated technique in order to reduce the dose to the spinal
cord. Any recommendations for the delineation, treatment
planning, or further questions for assessment, were in-
cluded in the feedback. No adaptations to the PREOPANC
protocol prescriptions were required.
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Fig. 3 Box plots of a the
conformity index (CI) of the
treatment plan, b the volume of
internal gross tumour volumes
(iGTVs) and planning target
volumes (PTV) and c the doses
to the organs at risk (OARs)
of the 11 institutions. Boxes:
median value and upper and
lower quartiles; whiskers: lowest
and highest data point within
1.5 × interquartile range; dots:
outliers
Discussion
In multicentre clinical trials, variation in protocol interpre-
tation and noncompliance are well-known pitfalls that may
lead to protocol deviations and discrepancies between par-
ticipating institutions. A modern protocol prescription of
radiotherapy leaves some freedom with regard to radiation
technique, but clearly describes target volumes, dose re-
quirements and constraints for OARs [23]. Quality assur-
ance in the form of a dummy run can be beneficial because
this can minimise clinical variations in treatment within
the trial. Previous dummy run studies (in various tumour
groups) showed that a dummy run ensures optimal radio-
therapy delivery based on recommendations and protocol
adaptations [13, 15, 16]. Our results showed acceptable de-
viations, i. e. essentially, inevitable interobserver variations
in target delineation, and no prescription adaptations were
required for the PREOPANC protocol. Because no adapta-
tions to the protocol were required we did not repeat the
dummy run and did not perform a central review of indi-
vidual patients prospectively.
In the present dummy run, we considered our assessment
(EV, GT) as the standard for evaluation of the pancreatic
tumour delineations of the ‘dummy’ patient. Consultation
between the QA team and the diagnostic radiologist con-
cerning the borders of the tumour took place before evalua-
tion of the delineations. We are aware that no gold standard
is available for the delineation of pancreatic tumours and
that evaluation of the delineations by two clinicians is sub-
jective and prone to error. Creating a consensus delineation
with more observers as a gold standard may be helpful, as
was shown in cervical cancer [24]. In pancreatic cancer, the
study of Carvatta et al. [25] proposed guidelines for high-
risk nodal areas and CTV delineation, showing acceptable
interobserver variation. No guideline is available for the
GTV delineation in pancreatic cancer and large interob-
server variation in pancreatic cancer delineation is reported
[26, 27]. For that reason, we did not provide a reference
contour.
The volumes of GTV and iGTV can be used as an
objective measure to indicate variation [28]. Our results
show that, for this ‘dummy’ patient, the mean iGTV vol-
ume of the pancreatic tumour was 41.5 cm3, with a ratio
between the largest and the smallest iGTV of 4.0. Two
earlier dummy runs, in three different cases of pancreatic
cancer, reported ratios of the largest to the smallest GTV
volume of 9, 3 and 6.8 [29, 30]. In the present study, the
questionnaire revealed that there is little experience in the
Netherlands with preoperative radiotherapy of pancreatic
tumours. The variation in delineation between observers
may decrease in time when institutions gain more experi-
ence.
Tumour extension outside the pancreas is an important
problem in the delineation of the GTV. Tumour extension
may result in only slight differences in density compared
with the surrounding fat tissue [29]. Also, no delineation
guidelines are available for pancreatic cancer, only for post-
operative radiotherapy of pancreatic cancer [31].
In our study, institution #10, applied the CTV margin be-
fore expanding the GTV to account for respiratory motion.
This suggested that the CTV was manually expanded in
the 10 respiratory phases to include the visible tumour; this
means that the microscopic tumour extensions are not prop-
erly accounted for in the CTV. As a result, the PTV margin
K
Strahlenther Onkol
used may be insufficient to account for all remaining uncer-
tainties. In this institution, the PTV volume (241 cm3) was
not the smallest of all the institutions. On an annual basis,
this institution treats (on average) only 5 patients with pan-
creatic cancer, implying that the experience in delineation
can be considered only moderate as compared with the other
institutions. Unfortunately we only noticed this deviation in
a later stage of the study, so this feedback was reported in
a later stage of the dummy run to the concerned institution.
The consequences of the minor deviations in iGTV delin-
eation for the PREOPANC trial outcome are unclear, as the
impact of interobserver variation on a trial outcome is not
yet fully explored [28]. However, by producing a clear pro-
tocol and using a dummy run to test protocol compliance we
aimed to reduce this variation between institutions. RTOG
studies reporting on deviations in delineation in pancreatic
trials showed unacceptable deviations in around 5% of the
cases in a total of four studies, without knowing the im-
pact on outcome [32]. In a multivariate analysis, one study
showed that the radiation therapy quality assurance (per-
protocol failure of adherence to guidelines) was significant
for survival of patients with pancreatic tumours [33].
One of our institutions used conformal 3-field treatment
planning, with a CI of 1.52 and higher doses to the spinal
cord and left kidney compared with the other institutions.
This illustrates that conformity and OAR sparing can be
improved with techniques such as VMAT or IMRT, as de-
scribed by Nabavizadeh et al. [34]. These latter authors
showed that the conformity for both VMAT and IMRT tech-
niques was superior compared with a 3D-CRT technique.
VMAT provided a comparable CI to IMRT, with reduced
mean doses to the PTV and an overall reduction in treat-
ment time [34].
It is known that respiratory-induced abdominal tumour
motion can be substantial. Almost all our institutions used
4DCT in the treatment of patients with pancreatic cancer,
taking into account the differences in position of the GTV
during the respiratory cycle. This can result in better cov-
erage of the pancreatic tumour within one fraction. Intra-
tumoural fiducial markers and daily online position ver-
ification are used to compensate for day-to-day position
variation [11, 35]. The above-mentioned procedures in ra-
diotherapy of pancreatic cancer are recommended in the
PREOPANC trial. Also, the interobserver variation in pan-
creatic tumour delineation is currently being quantified in
the Netherlands, by means of a study comparing delineation
on 3DCT and 4DCT.
Unfortunately, no quantitative evaluation of the variation
in delineations, such as the kappa index, could be performed
with the software used for the present study. This is a lim-
itation of this study. The kappa index can be used for mea-
suring observer agreement when there is no gold standard
[36]. However the added value of the kappa index in this
study would be limited since we only had a single dummy
patient. No other radiotherapy quality assurance measures
were undertaken, as the compliance to protocol prescrip-
tions was acceptable and the observed deviations were in-
evitable interobserver variations in target delineation. Al-
though guidelines are available for the postoperative set-
ting [31], no gold standard exists for preoperative target
delineation for pancreatic cancer. Also, since extensive QA
procedures are known to hamper accrual [37], we consid-
ered the value of adding prospective individual case review
(or other measures) to be too small to implement them.
Conclusion
In this dummy run, all participating institutions were al-
lowed to continue participation in the PREOPANC trial
since their compliance to the radiotherapy protocol had ac-
ceptable deviations, all of which were due to inevitable
interobserver variation in target delineation. A few recom-
mendations were made. Further studies are required to im-
prove visualisation of pancreatic cancer and the delineation
tools used, in order to decrease target delineation variation
between individual clinicians.
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